Optimization of orally bioavailable alkyl amine renin inhibitors.
Xu, Z., Cacatian, S., Yuan, J., Simpson, R.D., Jia, L., Zhao, W., Tice, C.M., Flaherty, P.T., Guo, J., Ishchenko, A., Singh, S.B., Wu, Z., McKeever, B.M., Scott, B.B., Bukhtiyarov, Y., Berbaum, J., Mason, J., Panemangalore, R., Cappiello, M.G., Bentley, R., Doe, C.P., Harrison, R.K., McGeehan, G.M., Dillard, L.W., Baldwin, J.J., Claremon, D.A.(2010) Bioorg Med Chem Lett 20: 694-699
- PubMed: 19959358 
- DOI: https://doi.org/10.1016/j.bmcl.2009.11.066
- Primary Citation of Related Structures:  
3KM4 - PubMed Abstract: 
Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC(50) of 0.83nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10mg/kg resulted in >20h reduction of blood pressure in a double transgenic rat model of hypertension.
Organizational Affiliation: 
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA.